AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26735264 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral α-lipoic acid (ALA), betamethasone injection, and NB-UVB
Number of subjects: 50
Study 26735264 — intervention group
Group type: COMPARATOR
Intervention: Placebo, betamethasone injection, and NB-UVB
Number of subjects: 50
Study 25046949 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Huaju Recipe (YHR) combined with routine therapy
Number of subjects: 43
Study 25046949 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy + placebo (Control)
Number of subjects: 43
Study 23520670 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol 20 mg
Number of subjects: 60
Study 23520670 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol 40 mg
Number of subjects: 60
Study 23520670 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anxiolytic premedication)
Number of subjects: 60
Study 19820226 — intervention group
Group type: EXPERIMENTAL
Intervention: New outcome measure instruments for vasculitis
Number of subjects: 0
Study 19820226 — intervention group
Group type: EXPERIMENTAL
Intervention: Core set of outcome measures for vasculitis
Number of subjects: 0
Study 19820226 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing projects providing data on outcomes
Number of subjects: 0
Study 18034677 — intervention group
Group type: EXPERIMENTAL
Intervention: Galvano-ceramic crowns
Number of subjects: 52
Study 18034677 — intervention group
Group type: COMPARATOR
Intervention: Metal-ceramic crowns
Number of subjects: 52
Study 15186875 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month educational diabetes programme tailored to Turkish patients, provided by Turkish bicultural female educators
Number of subjects: 54
Study 11413842 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS) 1 g twice daily on Day 1 and 1 g three times daily on Day 2
Number of subjects: 312
Study 11413842 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (PAR) 1 g twice daily on Day 1 and 1 g three times daily on Day 2
Number of subjects: 312
Study 11413842 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS)
Number of subjects: 312
Study 9065296 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic cryosurgery (group 1, n = 63)
Number of subjects: 123
Study 9065296 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical techniques (group 2, n = 60)
Number of subjects: 123
Study 7946588 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose gamma-interferon (gamma IFN) at doses of 100, 200, or 400 micrograms, administered daily or weekly for a minimum of 3 months after a 2-week cycle.
Number of subjects: 36
Study 7946588 — intervention group
Group type: COMPARATOR
Intervention: Comparison to other low-dose gamma IFN trials.
Number of subjects: 36
Study 3680556 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg oral doses
Number of subjects: 23
Study 3680556 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 200 mg/d PO
Number of subjects: 23
Study 3680556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 29132646 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable teams
Number of subjects: 46
Study 29132646 — intervention group
Group type: COMPARATOR
Intervention: Dynamic teams
Number of subjects: 46
Study 26469360 — intervention group
Group type: EXPERIMENTAL
Intervention: Active NMES + swallow exercise
Number of subjects: 170
Study 26469360 — intervention group
Group type: COMPARATOR
Intervention: Sham NMES + swallow exercise
Number of subjects: 170
Study 24650164 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime Time intervention
Number of subjects: 253
Study 20961633 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate PCI (IMM)
Number of subjects: 598
Study 20961633 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue PCI (RES)
Number of subjects: 598
Study 20961633 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Treatment Arm (STA)
Number of subjects: 598
Study 20565333 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine at 20 mg/day
Number of subjects: 63
Study 20565333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 20565333 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 63
Study 20565333 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurophysiological measurements
Number of subjects: 63
Study 17689932 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (TNFalpha inhibitor)
Number of subjects: 6
Study 16355744 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking towards the targets (depth-presentation condition)
Number of subjects: 0
Study 16355744 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking in a direction incompatible with the locations of the targets (width-presentation condition)
Number of subjects: 0
Study 16355744 — intervention group
Group type: EXPERIMENTAL
Intervention: Blindly walking in a direction other than toward the targets (depth-presentation condition)
Number of subjects: 0
Study 16355744 — intervention group
Group type: EXPERIMENTAL
Intervention: Blindly walking in a direction other than toward the targets (width-presentation condition)
Number of subjects: 0
Study 12062893 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg paroxetine
Number of subjects: 6
Study 12062893 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg paroxetine
Number of subjects: 6
Study 12062893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8848890 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 50 micrograms kg‐1 with atropine 20 micrograms kg‐1
Number of subjects: 80
Study 8848890 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg kg‐1 with atropine 10 micrograms kg‐1
Number of subjects: 80
Study 1982774 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg propiomazine
Number of subjects: 12
Study 100808 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine (10 mg)
Number of subjects: 24
Study 100808 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (100 mg)
Number of subjects: 24
Study 100808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31129129 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 0
Study 28837025 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin 0.3mg (Group A)
Number of subjects: 40
Study 28837025 — intervention group
Group type: COMPARATOR
Intervention: Triptorelin 0.4mg (Group B)
Number of subjects: 40
Study 27266362 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium-90 (90Y) radioembolization alone
Number of subjects: 23
Study 27266362 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium-90 (90Y) radioembolization with sorafenib
Number of subjects: 23
Study 27266362 — intervention group
Group type: COMPARATOR
Intervention: Control group (Yttrium-90 alone)
Number of subjects: 23
Study 23474109 — intervention group
Group type: EXPERIMENTAL
Intervention: High Ki67 staining index (Ki67-SI) ≥Q3
Number of subjects: 468
Study 23474109 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 468
Study 23474109 — intervention group
Group type: COMPARATOR
Intervention: RT with ADT
Number of subjects: 468
Study 23474109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki67-SI
Number of subjects: 468
Study 21113612 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour protocol at 60% of VO(2max)
Number of subjects: 27
Study 21113612 — intervention group
Group type: EXPERIMENTAL
Intervention: Adventure Race over 6 days at self-selected race pace (38% of VO(2max))
Number of subjects: 27
Study 21113612 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 27
Study 19049993 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate administration of misoprostol after mifepristone (600 microg vaginally)
Number of subjects: 0
Study 19049993 — intervention group
Group type: EXPERIMENTAL
Intervention: 36-38 h administration of misoprostol after mifepristone (600 microg vaginally)
Number of subjects: 0
Study 19049993 — intervention group
Group type: EXPERIMENTAL
Intervention: 36-38 h administration of misoprostol
Number of subjects: 0
Study 19049993 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate administration of misoprostol
Number of subjects: 0
Study 17182162 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cognitive support
Number of subjects: 81
Study 17182162 — intervention group
Group type: COMPARATOR
Intervention: High cognitive support
Number of subjects: 81
Study 17182162 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive functions measure (perseverative errors on the Wisconsin Card Sorting Test)
Number of subjects: 81
Study 17182162 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid intelligence measure (Cattell's culture fair test)
Number of subjects: 81
Study 14656755 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 696
Study 14656755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 696
Study 11231032 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched chain amino acids
Number of subjects: 0
Study 11231032 — intervention group
Group type: EXPERIMENTAL
Intervention: L-threonine with pyridoxal 5-phosphate
Number of subjects: 0
Study 11231032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9855514 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of sildenafil
Number of subjects: 27
Study 9855514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 7727908 — intervention group
Group type: EXPERIMENTAL
Intervention: Opiate sedation plus low dose midazolam (1 mg/hour)
Number of subjects: 0
Study 7727908 — intervention group
Group type: COMPARATOR
Intervention: Opiate sedation
Number of subjects: 0
Study 2536052 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive home visits every third month over 3 years
Number of subjects: 285
Study 2536052 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preventive home visits)
Number of subjects: 285
Study 2536052 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive home visits
Number of subjects: 285
Study 2536052 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 285
Study 5556052 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 23
Study 5556052 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 23
Study 30985449 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive IV fluid resuscitation strategy (≤ 60 mL/kg of IV fluid)
Number of subjects: 109
Study 30985449 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 109
Study 28453978 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-nasal administration of Oxytocin
Number of subjects: 90
Study 28453978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 25761587 — intervention group
Group type: EXPERIMENTAL
Intervention: dienogest + estradiol valerate (E2V) for 9 months
Number of subjects: 78
Study 25761587 — intervention group
Group type: COMPARATOR
Intervention: gonadotrophin‐releasing hormone analogue (GnRH‐a) monthly for 6 months
Number of subjects: 78
Study 25761587 — intervention group
Group type: EXPERIMENTAL
Intervention: dienogest + estradiol valerate (E2V)
Number of subjects: 78
Study 25761587 — intervention group
Group type: COMPARATOR
Intervention: gonadotrophin‐releasing hormone analogue (GnRH‐a)
Number of subjects: 78
Study 23825408 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal task with positive emotions
Number of subjects: 0
Study 21667768 — intervention group
Group type: EXPERIMENTAL
Intervention: Magical film (experimental group)
Number of subjects: 56
Study 21667768 — intervention group
Group type: COMPARATOR
Intervention: Nonmagical film (control group)
Number of subjects: 56
Study 19500383 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention including caregiver support groups and counselling
Number of subjects: 390
Study 19500383 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 390
Study 16763820 — intervention group
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATOC
Number of subjects: 15
Study 16763820 — intervention group
Group type: COMPARATOR
Intervention: [18F]FDG
Number of subjects: 15
Study 16763820 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 68Ga-DOTATOC and [18F]FDG
Number of subjects: 15
Study 15327620 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 600 microg (200 microg orally and 400 microg sublingually)
Number of subjects: 160
Study 15327620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 11315575 — intervention group
Group type: EXPERIMENTAL
Intervention: P-wave signal-averaging using MAC 5000 device
Number of subjects: 123
Study 11315575 — intervention group
Group type: EXPERIMENTAL
Intervention: P-wave signal-averaging
Number of subjects: 123
Study 9243239 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniocentesis (EA)
Number of subjects: 804
Study 9243239 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorion villus sampling (CVS)
Number of subjects: 804
Study 9243239 — intervention group
Group type: COMPARATOR
Intervention: Control (no invasive procedures)
Number of subjects: 804
Study 8044013 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine group (CMG) treated with Tongjingbao and Angelicae Complex Injection
Number of subjects: 50
Study 8044013 — intervention group
Group type: COMPARATOR
Intervention: Western medicine group (WMG) treated with Gentamycin, Dexamethasone, Chymotrypsin
Number of subjects: 50
Study 3255916 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation A of tripotassium dicitrato bismuthate (TDB)
Number of subjects: 0
Study 3255916 — intervention group
Group type: COMPARATOR
Intervention: Formulation B of tripotassium dicitrato bismuthate (TDB)
Number of subjects: 0
Study 28633477 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop diuretics (high doses)
Number of subjects: 0
Study 28633477 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics withdrawal
Number of subjects: 0
Study 28633477 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics (general use)
Number of subjects: 0
Study 28633477 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics decrease (from a small randomized study)
Number of subjects: 0
Study 28849302 — intervention group
Group type: COMPARATOR
Intervention: Education Group (EG)
Number of subjects: 138
Study 28849302 — intervention group
Group type: COMPARATOR
Intervention: Intervention Group (IG)
Number of subjects: 138
Study 28849302 — intervention group
Group type: COMPARATOR
Intervention: Education and Intervention Group (E + IG)
Number of subjects: 138
Study 28849302 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 138
Study 26096106 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete denture (CD) prosthesis
Number of subjects: 40
Study 23439417 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibram FiveFinger running shoes for 10 wk (experimental group)
Number of subjects: 36
Study 23439417 — intervention group
Group type: COMPARATOR
Intervention: Traditional running shoes for 10 wk (control group)
Number of subjects: 36
Study 21401865 — intervention group
Group type: EXPERIMENTAL
Intervention: rPSGL-Ig (1 mg/kg systemic dose with pretransplant allograft ex vivo treatment)
Number of subjects: 47
Study 21401865 — intervention group
Group type: EXPERIMENTAL
Intervention: rPSGL-Ig
Number of subjects: 47
Study 21401865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 18362297 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss group
Number of subjects: 75
Study 18362297 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 16520053 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniaturized CPB
Number of subjects: 40
Study 16520053 — intervention group
Group type: COMPARATOR
Intervention: Standard CPB
Number of subjects: 40
Study 12948258 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard ACTH (250 microg) test
Number of subjects: 16
Study 12948258 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose ACTH (1 microg) test
Number of subjects: 16
Study 12948258 — intervention group
Group type: COMPARATOR
Intervention: Both low dose and standard dose ACTH tests
Number of subjects: 16
Study 10890484 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine2-receptor antagonists or antacids
Number of subjects: 141887
Study 10890484 — intervention group
Group type: COMPARATOR
Intervention: No SU prophylaxis
Number of subjects: 141887
Study 10170453 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 2953
Study 10170453 — intervention group
Group type: COMPARATOR
Intervention: SSRIs (fluoxetine, fluvoxamine, sertraline, paroxetine)
Number of subjects: 2953
Study 10170453 — intervention group
Group type: COMPARATOR
Intervention: TCAs (amitriptyline, imipramine, desipramine, nortriptyline)
Number of subjects: 2953
Study 8213274 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 929
Study 2947462 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide metered-dose inhaler (40 micrograms four times a day)
Number of subjects: 164
Study 2947462 — intervention group
Group type: COMPARATOR
Intervention: Metaproterenol metered-dose inhaler (1,500 micrograms four times a day)
Number of subjects: 164
Study 2947462 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 164
Study 30462260 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifamycin SV‐MMX® 400 mg twice daily
Number of subjects: 835
Study 30462260 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily
Number of subjects: 835
Study 27467767 — intervention group
Group type: EXPERIMENTAL
Intervention: 1×4-min high-intensity interval training (1HIIT), 1×4 min bout at 85-95% HRpeak, three times/week
Number of subjects: 50
Study 27467767 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MICT), 30 min at 60-70% HRpeak, five times/week
Number of subjects: 50
Study 27467767 — intervention group
Group type: COMPARATOR
Intervention: 4×4-min high-intensity interval training (4HIIT), 4×4 min bouts at 85-95% HRpeak, three times/week
Number of subjects: 50
Study 24395069 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (FG) group (n = 48)
Number of subjects: 95
Study 24395069 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 47)
Number of subjects: 95
Study 24094794 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP-Imagery
Number of subjects: 114
Study 24094794 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP-Semantic
Number of subjects: 114
Study 24094794 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 114
Study 21094019 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated interpersonal cognitive‐behavioral group treatment (ICBT)
Number of subjects: 0
Study 21094019 — intervention group
Group type: COMPARATOR
Intervention: Wait list condition (WL)
Number of subjects: 0
Study 18283282 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training (PRT)
Number of subjects: 78
Study 16645969 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg/day
Number of subjects: 139
Study 16645969 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 7.5 mg/day
Number of subjects: 139
Study 16645969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 12553635 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure lanolin cream used twice daily for 4 weeks
Number of subjects: 92
Study 12553635 — intervention group
Group type: COMPARATOR
Intervention: Ammonium lactate 12% cream used twice daily for 4 weeks
Number of subjects: 92
Study 11023726 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral catheterization before vaginal cleansing
Number of subjects: 167
Study 11023726 — intervention group
Group type: COMPARATOR
Intervention: Urethral catheterization after vaginal cleansing
Number of subjects: 167
Study 8840633 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) 240 mg twice daily (Group 1)
Number of subjects: 63
Study 8840633 — intervention group
Group type: COMPARATOR
Intervention: Placebo I (Group 2)
Number of subjects: 63
Study 8840633 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 2.0 g twice daily (Group 3)
Number of subjects: 63
Study 8840633 — intervention group
Group type: COMPARATOR
Intervention: Placebo II (Group 4)
Number of subjects: 63
Study 1458144 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (60 mg/day); 14% required additional diuretics.
Number of subjects: 102
Study 1458144 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (40 mg/day); 76% required diuretics.
Number of subjects: 102
Study 6829919 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-chloroprocaine
Number of subjects: 60
Study 6829919 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 60
Study 31370811 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback Training Group (NF group)
Number of subjects: 179
Study 31370811 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate group (MPH group)
Number of subjects: 179
Study 29982727 — intervention group
Group type: EXPERIMENTAL
Intervention: GEN-003 30 µg antigen/25 µg adjuvant
Number of subjects: 0
Study 29982727 — intervention group
Group type: EXPERIMENTAL
Intervention: GEN-003 30 µg antigen/50 µg adjuvant
Number of subjects: 0
Study 29982727 — intervention group
Group type: EXPERIMENTAL
Intervention: GEN-003 30 µg antigen/75 µg adjuvant
Number of subjects: 0
Study 29982727 — intervention group
Group type: EXPERIMENTAL
Intervention: GEN-003 60 µg antigen/25 µg adjuvant
Number of subjects: 0
Study 29982727 — intervention group
Group type: EXPERIMENTAL
Intervention: GEN-003 60 µg antigen/50 µg adjuvant
Number of subjects: 0
Study 29982727 — intervention group
Group type: EXPERIMENTAL
Intervention: GEN-003 60 µg antigen/75 µg adjuvant
Number of subjects: 0
Study 29982727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29982727 — intervention group
Group type: EXPERIMENTAL
Intervention: GEN-003
Number of subjects: 0
Study 29982727 — intervention group
Group type: EXPERIMENTAL
Intervention: GEN-003 60 µg antigen plus 50 or 75 µg adjuvant
Number of subjects: 0